|
Antioxidants In Vitro is it a Need for Oral Precancerous Lesion
S Parthiban1, Joseph Arnold2, V Shankarram3, Tharani Kumar4, R Kadhiresan5
1 Reader, Department of Periodontics, Thai Moogambigai Dental College, Chennai, Tamil Nadu, India
2 Reader, Department of Oral and Maxillofacial Surgery, Thai Moogambigai Dental College, Chennai, Tamil Nadu, India
3 Professor, Department of Periodontics, Thai Moogambigai Dental College, Chennai, Tamil Nadu, India
4 Reader, Department of Oral and Maxilla Facial Surgery, Satyabhama University and Dental College, Chennai, Tamil Nadu, India
5 Reader, Department of Periodontics, Sree Venketeswara Dental College and Hospital, Chennai, Tamil Nadu, India
Correspondence Address:
S Parthiban
Reader, Department of Periodontics, Thai Moogambigai Dental College, Chennai, Tamil Nadu, India
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
Background: At the backdrop of the debatable role of antioxidant (AO) therapy, patients with oral premalignant lesions (OPLs) were evaluated to assess the logic behind AO t herapies.
Subjects and Methods: Oxidative stress and AO status have to be assessed in OPLs patients and compared with healthy individuals, classify into study groups which could be useful in selection of ideal patients requiring AO therapy. Total 121 subjects were included for this study n = 76 were with OPL, n = 45 were healthy controls. Serum levels of reactive oxygen species (ROS) (malondialdehyde [MDA]) and AO enzymes super oxide dismutase (SOD), catalase and glutathione peroxidase (GSH-PX) were evaluated in blood serum and grouped under levels of ROS and AO enzymes activity.
Results: In 76 OPL patients increase in the in serum (MDA) level observed along with a decrease in activity of AO enzymes, SOD, catalase, and GSH-PX in comparison to 45 healthy subjects. classification of OPL patients shown that 38.15% Group I patients did not have any significant change in oxidative stress. Group II (21.05%) patients though had enhanced stress, their AO enzymes level were normal these two groups did not require AO treatment. However, 10.5% of patients Group III had normal MDA with low AO defense and whereas 30.2% Group IV patients had an abnormality in all parameters, last two groups to be aided by AO therapy.
Conclusion: Prior valuation of the oxidative stress and AO status in the patients with OPL can be done to reduce the abuse of severe AOs medication. |
